文献速递消化、代谢与肾脏急症

电子烟对比伐尼克兰和尼古丁咀嚼胶辅助戒烟疗效的随机临床试验

Efficacy of Electronic Cigarettes vs Varenicline and Nicotine Chewing Gum as an Aid to Stop Smoking: A Randomized Clinical Trial.
PubMed 文献 · JAMA Intern Med · 2024-01-01
一句话结论在轻度行为支持下,电子烟6个月戒断率不劣于伐尼克兰且优于尼古丁咀嚼胶,但6个月时62.8%电子烟组仍在使用电子烟。

该随机临床试验在中国7个中心纳入每日吸烟≥10支且有戒烟意愿的成人1068例,随机分配至电子烟组409例、伐尼克兰组409例、尼古丁咀嚼胶组250例,均治疗12周并给予最低限度行为支持。6个月经呼出气一氧化碳验证的持续戒断率分别为电子烟组15.7%、伐尼克兰组14.2%、尼古丁咀嚼胶组8.8%;电子烟不劣于伐尼克兰(绝对风险降低1.47%,95%CI -1.41%至4.34%),优于尼古丁咀嚼胶(OR 1.92,95%CI 1.15-3.21)。治疗依从性前3个月三组相似,但6个月时电子烟组257例(62.8%)仍在继续使用电子烟,另两组无继续使用。最常见不良反应为咽喉刺激、口腔刺激和恶心,未记录严重不良事件。

要点

  • 6个月生物验证戒断率:电子烟组15.7%(64例)、伐尼克兰组14.2%(58例)、尼古丁咀嚼胶组8.8%(22例)。
  • 电子烟对比伐尼克兰不劣(绝对风险降低1.47%,95%CI -1.41%至4.34%),对比尼古丁咀嚼胶更优(OR 1.92,95%CI 1.15-3.21)。
  • 电子烟组6个月时257例(62.8%)仍在使用电子烟,伐尼克兰和尼古丁咀嚼胶组无继续使用。
  • 最常见不良反应:电子烟组咽喉刺激7.8%(32例)和口腔刺激6.9%(28例);伐尼克兰组恶心8.8%(36例);咀嚼胶组咽喉刺激8.0%(20例)和口腔刺激8.8%(22例);无严重不良事件。
  • 所有治疗均仅伴最低限度行为支持(邀请加入自助网络论坛),前3个月三组治疗依从性相似。

适用人群与场景

  • 每日吸烟至少10支且有戒烟意愿的成人,未使用戒烟药物或电子烟,愿意使用研究提供的任何产品。
  • 研究在中国7个中心开展,于2021年5月首次招募参与者,数据分析于2022年12月进行。
  • 研究纳入的1068例参与者中357例(33.5%)为女性,平均(标准差)年龄33.9(3.1)岁。

诊断标准与关键阈值

  • 主要结局为6个月时经呼出气一氧化碳读数(<8 ppm)验证的持续戒烟。
  • 失访参与者按非戒断者计算。

处置流程与药物剂量

  • 电子烟组:使用烟弹式电子烟,前2周尼古丁盐浓度30 mg/mL,之后50 mg/mL,提供12周。
  • 伐尼克兰组:0.5 mg每日一次用3天;0.5 mg每日两次用4天;之后1 mg每日两次,提供12周。
  • 尼古丁咀嚼胶组:每日吸烟≤20支者用2 mg,每日吸烟>20支者用4 mg,提供12周。
  • 所有组均伴最低限度行为支持(邀请加入自助网络论坛)。

研究设计与关键结果

  • 研究为在中国7个中心开展的随机临床试验,共纳入1068例参与者,随机分配至电子烟组409例(38.3%)、伐尼克兰组409例(38.3%)、尼古丁咀嚼胶组250例(23.4%)。
  • 6个月生物验证戒断率:电子烟组15.7%(64例)、伐尼克兰组14.2%(58例)、尼古丁咀嚼胶组8.8%(22例)。
  • 电子烟组对比伐尼克兰组的绝对风险降低为1.47%(95%CI -1.41%至4.34%),达到非劣效。
  • 电子烟组对比尼古丁咀嚼胶组的OR为1.92(95%CI 1.15-3.21),电子烟组戒断率更高。
  • 前3个月治疗依从性三组相似;6个月时电子烟组257例(62.8%)仍在使用电子烟,另两组无继续使用。
  • 最常见不良反应:电子烟组咽喉刺激7.8%(32例)、口腔刺激6.9%(28例);伐尼克兰组恶心8.8%(36例);尼古丁咀嚼胶组咽喉刺激8.0%(20例)、口腔刺激8.8%(22例);未记录严重不良事件。

证据类型、等级与局限

  • 证据类型:随机临床试验。
  • 试验注册:中国临床试验注册中心 ChiCTR2100048156。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,当所有治疗均伴最低限度行为支持时,电子烟的戒烟疗效不劣于伐尼克兰且优于尼古丁咀嚼胶。
  • 电子烟组6个月时62.8%仍在继续使用电子烟,原文未报告长期使用电子烟的相关推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Electronic cigarettes (ECs) are often used by smokers as an aid to stopping smoking, but evidence is limited regarding their efficacy compared with nicotine replacement therapy (NRT), and no evidence is available on how their efficacy compares with that of varenicline.

OBJECTIVE: To evaluate whether ECs are superior to NRT and noninferior to varenicline in helping smokers quit.

DESIGN, SETTING, AND PARTICIPANTS: This was a randomized clinical trial conducted at 7 sites in China and including participants who were smoking at least 10 cigarettes per day and motivated to quit, not using stop-smoking medications or EC, and willing to use any of the study products. Participants were first recruited in May 2021, and data analysis was conducted in December 2022.

INTERVENTIONS: A cartridge-based EC (30 mg/mL nicotine salt for 2 weeks and 50 mg/mL after that), varenicline (0.5 mg, once a day for 3 days; 0.5 mg, twice a day for 4 days; and 1 mg, twice a day, after that), and 2 mg (for smokers of ≤20 cigarettes per day) or 4 mg (>20 cigarettes per day) nicotine chewing gum, all provided for 12 weeks and accompanied by minimal behavioral support (an invitation to join a self-help internet forum).

MAIN OUTCOMES AND MEASURES: The primary outcome was sustained abstinence from smoking at 6 months as validated by an expired-air carbon monoxide reading (<8 parts per million). Participants lost to follow-up were included as nonabstainers.

RESULTS: Of 1068 participants, 357 (33.5%) were female, and the mean (SD) age was 33.9 (3.1) years. A total of 409 (38.3%), 409 (38.3%), and 250 (23.4%) participants were randomized to the EC, varenicline, and NRT arms, respectively. The 6-month biochemically validated abstinence rates were 15.7% (n = 64), 14.2% (n = 58), and 8.8% (n = 22) in the EC, varenicline, and NRT study arms, respectively. The quit rate in the EC arm was noninferior to the varenicline arm (absolute risk reduction, 1.47%; 95% CI, -1.41% to 4.34%) and higher than in the NRT arm (odds ratio, 1.92; 95% CI, 1.15-3.21). Treatment adherence was similar in all study arms during the initial 3 months, but 257 participants (62.8%) in the EC arm were still using ECs at 6 months, with no further use in the 2 other study arms. The most common adverse reactions were throat irritation (32 [7.8%]) and mouth irritation (28 [6.9%]) in the EC arm, nausea (36 [8.8%]) in the varenicline arm, and throat irritation (20 [8.0%]) and mouth irritation (22 [8.8%]) in the NRT arm. No serious adverse events were recorded.

CONCLUSIONS AND RELEVANCE: The results of this randomized clinical trial found that when all treatments were provided with minimal behavior support, the efficacy of EC was noninferior to varenicline and superior to nicotine chewing gum.

TRIAL REGISTRATION: Chinese Clinical Trial Registry: ChiCTR2100048156.

来源:JAMA Intern Med,查看原文。版权归原作者所有。

参考来源

  1. Lin HX, Liu Z, Hajek P, et al. Efficacy of Electronic Cigarettes vs Varenicline and Nicotine Chewing Gum as an Aid to Stop Smoking: A Randomized Clinical Trial. JAMA Intern Med. 2024. PMID: 38285562. doi:10.1001/jamainternmed.2023.7846

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。